WHY IT MATTERS: Seniors using CBD products need to know that without third-party lab verification and a conversation with a knowledgeable clinician, they may be exposing themselves to inconsistent doses, contaminants, or unrecognized interactions with their existing medications. CLINICAL OVERVIEW: CBD use among older adults is growing rapidly, driven by interest in managing chronic pain, sleep disturbances, anxiety, and inflammation without the intoxicating effects associated with THC. The endocannabinoid system, which modulates these physiological processes, undergoes changes with aging, and there is emerging evidence that cannabinoid-based interventions may help restore some of that regulatory balance.
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
WHY IT MATTERS: If you or a loved one is living with Alzheimer’s-related agitation, the expansion of this clinical trial means more opportunities to access investigational cannabinoid therapy and brings us closer to having FDA-reviewed evidence for cannabis-based treatment options in dementia care. CLINICAL OVERVIEW: The expansion of clinical trial sites for IGC Pharma’s Phase 2 CALMA trial investigating cannabinoid-based therapy for Alzheimer’s-associated agitation represents a meaningful step in building the evidence base for cannabis medicine in neurodegenerative disease. Alzheimer’s-related behavioral symptoms like agitation and aggression are notoriously difficult to manage with conventional medications, and cannabinoid therapies have shown early promise in addressing neuroinflammation and behavioral dysregulation through endocannabinoid system modulation.
Cannabis Use in Older Adults Is Rising—Now What?
Older adults are turning to cannabis in record numbers—but you wouldn’t know it from most medical offices. This isn’t a rebellion—it’s a quiet referendum on how we handle chronic illness, aging, and autonomy. The question isn’t whether it’s happening—the question is: where are the doctors?